Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Authors
Keywords
-
Journal
Nature Communications
Volume 7, Issue -, Pages 11579
Publisher
Springer Nature
Online
2016-05-13
DOI
10.1038/ncomms11579
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Differential binding of prohibitin-2 to estrogen receptor α and to drug-resistant ERα mutants
- (2015) Takeru Chigira et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The changing role of ER in endocrine resistance
- (2015) Agostina Nardone et al. BREAST
- Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration
- (2015) J. S. Frenel et al. CLINICAL CANCER RESEARCH
- ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients
- (2015) D. Chu et al. CLINICAL CANCER RESEARCH
- Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients
- (2015) P. Wang et al. CLINICAL CANCER RESEARCH
- Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor-Positive Metastatic Breast Cancer
- (2015) D. S. Guttery et al. CLINICAL CHEMISTRY
- Short report: MonitoringESR1mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer
- (2015) David Sefrioui et al. INTERNATIONAL JOURNAL OF CANCER
- Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
- (2015) Andiliy Lai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist
- (2015) Chris De Savi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
- (2015) Isaac Garcia-Murillas et al. Science Translational Medicine
- Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
- (2015) Gaia Schiavon et al. Science Translational Medicine
- Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples
- (2014) Timothy R. Wilson et al. BREAST CANCER RESEARCH AND TREATMENT
- Emergence of Constitutively Active Estrogen Receptor- Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
- (2014) R. Jeselsohn et al. CLINICAL CANCER RESEARCH
- Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
- (2014) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- D538G Mutation in Estrogen Receptor- : A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
- (2013) K. Merenbakh-Lamin et al. CANCER RESEARCH
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- The search for ESR1 mutations in breast cancer
- (2013) Steffi Oesterreich et al. NATURE GENETICS
- Circulating tumour cells and cell-free DNA as tools for managing breast cancer
- (2013) Leticia De Mattos-Arruda et al. Nature Reviews Clinical Oncology
- Circulating Tumor DNA to Monitor Metastatic Breast Cancer
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
- (2013) Shunqiang Li et al. Cell Reports
- The Life History of 21 Breast Cancers
- (2012) Serena Nik-Zainal et al. CELL
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating mutant DNA to assess tumor dynamics
- (2008) Frank Diehl et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More